Ocugen

Ocugen is a biotechnology company with a strong focus on pioneering gene and cell therapies as well as vaccines aimed at improving global health. Established in 2013 and headquartered in the United States, Ocugen's aim is to bring hope and healing to patients worldwide through innovative scientific advancements. Their groundbreaking modifier gene therapy platform has the potential to address multiple retinal diseases with a single product, while also making headway in infectious diseases research for the betterment of public health and orthopedic diseases to meet unmet medical needs. The company recently received a substantial $30.00M post-IPO debt investment on November 7, 2024 from Avenue Capital Group, showcasing the confidence and support of notable investors in Ocugen's vision. With their mission to approach healthcare innovation with purpose and agility, Ocugen is positioning itself to be at the forefront of transformative advancements in the biopharma, biotechnology, and healthcare industries.